CORDIS
EU research results

CORDIS

English EN
Modulation of glycolytic flux as a new approach for treatment of atherosclerosis and plaque stabilization: a multidisciplinary study

Modulation of glycolytic flux as a new approach for treatment of atherosclerosis and plaque stabilization: a multidisciplinary study

Objective

The mission of MoGlyNet is to define a joint doctorate educational training model in Drug Discovery and Development where Academia and Industry join their forces for:
- creating a common platform of knowledge and language for early stage researchers (ESR) working in the Drug Discovery and Development area aiming to convey complementary pharma-skills
- exploiting this platform to train a new generation of cutting-edge researchers and professionals highly attractive for employment by the European Pharma-industry
- establishing structures for long-term cooperation, strengthening the relationships among the leading Universities and Pharma-enterprises and to continuously develop the research training platform that European industry relies on.
To achieve the above objectives the main tasks of MoGlyNet are:
- to attract/train 12 ESRs in optimization joint academic/industrial program of cutting-edge training-by-research, high quality supervision, complementary and transferable Pharma-skills training, inter-network secondments, and workshops/Summer Schools
- to pursue an innovative research project that will tackle a timely and important scientific problem with a multidisciplinary approach (from molecular modelling to in vivo studies). Atherosclerosis is an aging-related disease and our research approach for a better therapy of atherosclerosis will be focused on the PFKFB3 enzyme, a key player in glycolysis/oxidative stress and therefore in pathological angiogenesis
- to build a solid foundation for long-term European excellence in this field by disseminating MoGlyNet research/training outcomes and best practice into the partners Doctoral Schools, and by fostering long-term partnerships and collaborations that will outlast the Consortium
- to transfer expertise/know-how among the Consortium participants and to external groups via networking activities, intersectorial exposure, secondments, workshops, sharing of learning material, public engagement and outreach activities

Coordinator

UNIVERSITA DEGLI STUDI DI MILANO

Address

Via Festa Del Perdono 7
20122 Milano

Italy

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 032 245,28

Participants (4)

Sort alphabetically

Sort by EU Contribution

Expand all

THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN

United Kingdom

EU Contribution

€ 546 575,76

UNIVERSITEIT ANTWERPEN

Belgium

EU Contribution

€ 501 120

UNIVERSITAT DE BARCELONA

Spain

EU Contribution

€ 495 745,92

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 510 748,56

Partners (8)

Sort alphabetically

Expand all

BAYER

BIOMAX INFORMATICS AG

EIPG

HistoGeneX N.V.

KEMOTECH SRL

LINKCARE HEALTH SERVICES SL

PHARMINTRACO

PPD

Project information

Grant agreement ID: 675527

Status

Ongoing project

  • Start date

    1 September 2015

  • End date

    31 August 2019

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 086 435,52

  • EU contribution

    € 3 086 435,52

Coordinated by:

UNIVERSITA DEGLI STUDI DI MILANO

Italy